Effects of XFG-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation

SARS-CoV-2 antigenic evolution continues to challenge strain-matched vaccination. For the 2026-27 season, the European Medicines Agency (EMA) identified XFG as the preferred antigen within the JN.1 family and Comirnaty XFG was authorised in the European Union in July, 2026. We studied 22 participants who received 30 microg of mRNA encoding XFG (Comirnaty XFG, BioNTech/Pfizer, Mainz, Germany) in September, 2026 and had paired serum available before vaccination and median 14 days afterwards. Median Wuhan-Hu-1 S1-specific IgG increased from 1600 BAU/mL (IQR 1118-2926) to 2914 BAU/mL (2117-4468),

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.